{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:10:38Z","timestamp":1778523038383,"version":"3.51.4"},"reference-count":250,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Sj\u00f6gren\u2019s Disease is an autoimmune epithelitis targeting the exocrine glands, predominantly the salivary and lacrimal glands, resulting in the major symptoms of dry mouth and dry eyes. The aim of this study is to review the pertinent literature on studies linking the oral manifestations of SjD patients, with the underlying molecular events driving SjD pathogenesis. These include mechanisms inducing innate sensing in salivary gland epithelial cells, activation of interferon signaling pathway, amplification of cytokines and chemokines, and orchestration of the inflammatory milieu in salivary glands, as well as mechanisms inducing salivary epithelial tissue destruction and secretory dysfunction, such as programmed cell death pathways, mitochondrial dysfunction, structural disorganization, loss of junctional integrity, and quantitative and qualitative aberrations in salivary secretory process.<\/jats:p>","DOI":"10.3390\/ijms27094144","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:03:37Z","timestamp":1778144617000},"page":"4144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Insights into Oral Manifestations in Sj\u00f6gren\u2019s Disease"],"prefix":"10.3390","volume":"27","author":[{"given":"Konstantina","family":"Xanthopoulou","sequence":"first","affiliation":[{"name":"School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Siatra","sequence":"additional","affiliation":[{"name":"School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8834-6078","authenticated-orcid":false,"given":"Konstantinos I.","family":"Tosios","sequence":"additional","affiliation":[{"name":"School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-4804","authenticated-orcid":false,"given":"Eleni-Marina","family":"Kalogirou","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Metropolitan College, 15125 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"ref_1","first-page":"2336","article-title":"Pathogenesis of Sjogren\u2019s disease: One year in review 2024","volume":"42","author":"Baldini","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Qi, W., Tian, J., Wang, G., Yan, Y., Wang, T., Wei, Y., Wang, Z., Zhang, G., Zhang, Y., and Wang, J. (2024). Advances in cellular and molecular pathways of salivary gland damage in Sjogren\u2019s syndrome. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1405126"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/art.41676","article-title":"Sjogren\u2019s Disease, Not Syndrome","volume":"73","author":"Baer","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","article-title":"2023 International Rome consensus for the nomenclature of Sjogren disease","volume":"21","author":"Baer","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sjogren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/annrheumdis-2016-209952","article-title":"Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren\u2019s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjogren Project Consortium","volume":"76","author":"Zeher","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/rheumatology\/keab032","article-title":"Childhood-onset of primary Sjogren\u2019s syndrome: Phenotypic characterization at diagnosis of 158 children","volume":"60","author":"Vissink","year":"2021","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e004426","DOI":"10.1136\/rmdopen-2024-004426","article-title":"Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjogren\u2019s disease","volume":"10","author":"Luciano","year":"2024","journal-title":"RMD Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50098","DOI":"10.18632\/oncotarget.15100","article-title":"Predictable biomarkers of developing lymphoma in patients with Sjogren syndrome: A nationwide population-based cohort study","volume":"8","author":"Chiu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/imj.16395","article-title":"The diagnosis and misdiagnosis of Sjogren disease","volume":"54","author":"Lee","year":"2024","journal-title":"Intern. Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1093\/rheumatology\/kez052","article-title":"Lymphomas complicating primary Sjogren\u2019s syndrome: From autoimmunity to lymphoma","volume":"60","author":"Nocturne","year":"2021","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.coi.2025.102717","article-title":"Markers predicting lymphoma development in Sjogren disease: Current status and future perspectives","volume":"99","author":"Panagiotopoulos","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for Primary Sjogren\u2019s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.2023-0247","article-title":"Seronegative Sjogren Syndrome: A Forgotten Entity?","volume":"51","author":"Lee","year":"2023","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sjogren\u2019s syndrome: A systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Stankeviciene, I., Puriene, A., Mieliauskaite, D., Stangvaltaite-Mouhat, L., and Aleksejuniene, J. (2021). Detection of xerostomia, Sicca, and Sjogren\u2019s syndromes in a national sample of adults. BMC Oral. Health, 21.","DOI":"10.1186\/s12903-021-01917-1"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, S.C., Lu, M.C., and Koo, M. (2025). Oral Manifestations of Sjogren\u2019s Syndrome: Recognition, Management, and Interdisciplinary Care. Medicina, 62.","DOI":"10.3390\/medicina62010005"},{"key":"ref_18","first-page":"441","article-title":"What rheumatologists should know about orofacial manifestations of autoimmune rheumatic diseases","volume":"56","author":"Abrao","year":"2016","journal-title":"Rev. Bras. Reumatol. Engl. Ed."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6061825","DOI":"10.1155\/2018\/6061825","article-title":"Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management","volume":"2018","author":"Saccucci","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/odi.12526","article-title":"IgG4-related sialadenitis and Sjogren\u2019s syndrome","volume":"23","author":"Fragoulis","year":"2017","journal-title":"Oral Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Maslinska, M., and Kostyra-Grabczak, K. (2024). Immunoglobulin G4 in primary Sjogren\u2019s syndrome and IgG4-related disease\u2014Connections and dissimilarities. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1376723"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bjoms.2016.10.021","article-title":"Differential diagnosis of IgG4-related sialadenitis, primary Sjogren syndrome, and chronic obstructive submandibular sialadenitis","volume":"55","author":"Hong","year":"2017","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1093\/rheumatology\/key360","article-title":"Innate immunity and interferons in the pathogenesis of Sjogren\u2019s syndrome","volume":"60","author":"Bodewes","year":"2021","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the pathophysiology and treatment of primary Sjogren syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhan, Q., Zhang, J., Lin, Y., Chen, W., Fan, X., and Zhang, D. (2023). Pathogenesis and treatment of Sjogren\u2019s syndrome: Review and update. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1127417"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2024.2312216","article-title":"New investigational drugs to treat Sjogren\u2019s syndrome: Lessons learnt from immunology","volume":"33","author":"Zhou","year":"2024","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dong, Y., Wang, T., and Wu, H. (2024). The role of cytokines from salivary gland epithelial cells in the immunopathology of Sjogren\u2019s syndrome. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1443455"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tan, Z., Wang, L., and Li, X. (2022). Composition and regulation of the immune microenvironment of salivary gland in Sjogren\u2019s syndrome. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.967304"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jleuko\/qiad049","article-title":"The role of epithelial cells in the immunopathogenesis of Sjogren\u2019s syndrome","volume":"115","author":"Tang","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sjogren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yura, Y., and Hamada, M. (2023). Outline of Salivary Gland Pathogenesis of Sjogren\u2019s Syndrome and Current Therapeutic Approaches. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311179"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Noll, B., Beckman, M., Bahrani Mougeot, F., and Mougeot, J.L. (2024). Exploring Salivary Epithelial Dysfunction in Sjogren\u2019s Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094973"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/odi.12105","article-title":"Oral manifestations and their treatment in Sjogren\u2019s syndrome","volume":"20","author":"Gonzalez","year":"2014","journal-title":"Oral Dis."},{"key":"ref_34","first-page":"387","article-title":"Oral involvement in patients with primary Sjogren\u2019s syndrome. Multidisciplinary care by dentists and rheumatologists","volume":"11","author":"Hernandez","year":"2015","journal-title":"Reumatol. Clin."},{"key":"ref_35","first-page":"e391","article-title":"Oral lesions in Sjogren\u2019s syndrome: A systematic review","volume":"23","author":"Serrano","year":"2018","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_36","first-page":"97","article-title":"Systemic manifestations of primary Sjogren\u2019s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients","volume":"37","author":"Retamozo","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_37","first-page":"980","article-title":"Sjogren\u2019s syndrome","volume":"20","author":"Andre","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.oooo.2012.05.009","article-title":"Clinical assessment of oral dryness: Development of a scoring system related to salivary flow and mucosal wetness","volume":"114","author":"Osailan","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1038\/s41598-019-43714-5","article-title":"Elevated cytokine levels in tears and saliva of patients with primary Sjogren\u2019s syndrome correlate with clinical ocular and oral manifestations","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3899\/jrheum.180101","article-title":"Tongue Atrophy in Sjogren Syndrome Patients with Mucosa-associated Lymphoid Tissue Lymphoma: Autoimmune Epithelitis beyond the Epithelial Cells of Salivary Glands?","volume":"45","author":"Zampeli","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Liao, R., Yang, H.T., Li, H., Liu, L.X., Li, K., Li, J.J., Liang, J., Hong, X.P., Chen, Y.L., and Liu, D.Z. (2021). Recent Advances of Salivary Gland Biopsy in Sjogren\u2019s Syndrome. Front. Med., 8.","DOI":"10.3389\/fmed.2021.792593"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0030-4220(74)90417-4","article-title":"The histopathology of Sjogren\u2019s syndrome in labial salivary gland biopsies","volume":"37","author":"Greenspan","year":"1974","journal-title":"Oral Surg. Oral Med. Oral Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Caraba, A., Roman, D., Crisan, V., Iurciuc, S., and Iurciuc, M. (2024). Salivary Flow Rate in Patients with Sjogren\u2019s Syndrome: Correlations with Salivary Gland Ultrasound Findings and Biomarkers of Disease Activity. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010101"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"105479","DOI":"10.1016\/j.jbspin.2022.105479","article-title":"Autoimmune epithelitis in primary Sjogren\u2019s syndrome","volume":"90","author":"Desvaux","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/S2665-9913(20)30038-2","article-title":"Rationale for CD40 pathway blockade in autoimmune rheumatic disorders","volume":"2","author":"Pucino","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.oooo.2025.04.171","article-title":"Salivary Th17-associated cytokines as potential biomarkers in primary Sjogren\u2019s Disease","volume":"140","author":"Florezi","year":"2025","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2018-213929","article-title":"Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD\/ShiLtJ mouse model of Sjogren\u2019s syndrome","volume":"78","author":"Wieczorek","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.imlet.2020.07.005","article-title":"Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of non-obese diabetic mice with Sjogren\u2019s syndrome","volume":"226","author":"Zhou","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjogren\u2019s disease (TWINSS): Week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sjogren\u2019s disease: A randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"Baer","year":"2024","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1246818","DOI":"10.1155\/2018\/1246818","article-title":"Current and Emerging Evidence for Toll-Like Receptor Activation in Sjogren\u2019s Syndrome","volume":"2018","author":"Kiripolsky","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"152062","DOI":"10.1016\/j.semarthrit.2022.152062","article-title":"Immunopathogenesis of Sjogren\u2019s syndrome: Current state of DAMPs","volume":"56","author":"Ming","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Shimizu, T., Nakamura, H., and Kawakami, A. (2021). Role of the Innate Immunity Signaling Pathway in the Pathogenesis of Sjogren\u2019s Syndrome. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063090"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Nishihata, S.Y., Shimizu, T., Umeda, M., Furukawa, K., Ohyama, K., Kawakami, A., and Nakamura, H. (2023). The Toll-like Receptor 7-Mediated Ro52 Antigen-Presenting Pathway in the Salivary Gland Epithelial Cells of Sjogren\u2019s Syndrome. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134423"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Punnanitinont, A., Kasperek, E.M., Kiripolsky, J., Zhu, C., Miecznikowski, J.C., and Kramer, J.M. (2022). TLR7 agonism accelerates disease in a mouse model of primary Sjogren\u2019s syndrome and drives expansion of T-bet(+) B cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1034336"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0714.2012.01181.x","article-title":"Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling","volume":"42","author":"Nandula","year":"2013","journal-title":"J. Oral Pathol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1601-0825.2011.01839.x","article-title":"Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjogren\u2019s syndrome-like disease","volume":"17","author":"Nandula","year":"2011","journal-title":"Oral Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"24244","DOI":"10.1038\/srep24244","article-title":"ALX\/FPR2 Modulates Anti-Inflammatory Responses in Mouse Submandibular Gland","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gilboa-Geffen, A., Wolf, Y., Hanin, G., Melamed-Book, N., Pick, M., Bennett, E.R., Greenberg, D.S., Lester, S., Rischmueller, M., and Soreq, H. (2011). Activation of the alternative NFkappaB pathway improves disease symptoms in a model of Sjogren\u2019s syndrome. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028727"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Punnanitinont, A., Biswas, S., Kasperek, E.M., Osinski, J., Zhu, C., Miecznikowski, J.C., Romano, R.A., and Kramer, J.M. (2024). Tlr7 drives sex- and tissue-dependent effects in Sjogren\u2019s disease. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1434269"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/art.42844","article-title":"Amplified Type I Interferon Response in Sjogren\u2019s Disease via Ectopic Toll-Like Receptor 7 Expression in Salivary Gland Epithelial Cells Induced by Lysosome-Associated Membrane Protein 3","volume":"76","author":"Nakamura","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhang, T., Guo, Z., Pu, J., Riaz, F., Feng, R., Fang, X., Song, J., Liang, Y., and Wu, Z. (2021). The Efficiency of Hydroxychloroquine for the Treatment of Primary Sjogren\u2019s Syndrome: A Systematic Review and Meta-Analysis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.693796"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of Severe Fatigue Following Nuclease Therapy in Patients with Primary Sjogren\u2019s Syndrome: A Randomized Clinical Trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2478\/rir-2022-0017","article-title":"JAK\/STAT Pathway Targeting in Primary Sjogren Syndrome","volume":"3","author":"Gandolfo","year":"2022","journal-title":"Rheumatol. Immunol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102703","DOI":"10.1016\/j.coi.2025.102703","article-title":"Interferons in Sjogren\u2019s disease: Current status and future prospects","volume":"98","author":"Raftopoulou","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"ref_66","first-page":"59","article-title":"Type I Interferons in the Pathogenesis and Treatment of Sj\u00f6gren\u2019s Syndrome: An Update","volume":"9","author":"Sun","year":"2022","journal-title":"Rheumatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1007\/s10528-024-10750-4","article-title":"Weighted Gene Co-expression Network Analysis and Machine Learning Validation for Identifying Major Genes Related to Sjogren\u2019s Syndrome","volume":"63","author":"Luo","year":"2025","journal-title":"Biochem. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15169","DOI":"10.1038\/s41598-020-71669-5","article-title":"LAMP3 induces apoptosis and autoantigen release in Sjogren\u2019s syndrome patients","volume":"10","author":"Tanaka","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sjogren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.42540","article-title":"Lysosome-Associated Membrane Protein 3 Induces Lysosome-Dependent Cell Death by Impairing Autophagic Caspase 8 Degradation in the Salivary Glands of Individuals with Sjogren\u2019s Disease","volume":"75","author":"Nakamura","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"103037","DOI":"10.1016\/j.jaut.2023.103037","article-title":"hsa-miR-424-5p and hsa-miR-513c-3p dysregulation mediated by IFN-gamma is associated with salivary gland dysfunction in Sjogren\u2019s syndrome patients","volume":"138","author":"Carvajal","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12865","article-title":"Expression of type III interferons (IFNlambdas) and their receptor in Sjogren\u2019s syndrome","volume":"186","author":"Apostolou","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_73","first-page":"31","article-title":"Increased expression of interferon-lambda in minor salivary glands of patients with primary Sjogren\u2019s syndrome and its synergic effect with interferon-alpha on salivary gland epithelial cells","volume":"36","author":"Ha","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/ard-2023-224842","article-title":"Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjogren\u2019s disease","volume":"83","author":"Gupta","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/art.40589","article-title":"JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sjogren\u2019s Syndrome","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjogren\u2019s syndrome: A randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"ref_77","first-page":"2437","article-title":"Tofacitinib alleviated salivary gland inflammation and reduced the percentages of effector T cells in murine Sjogren\u2019s disease","volume":"42","author":"Liu","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2625552","DOI":"10.1080\/07853890.2026.2625552","article-title":"JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17\/Treg imbalance in a Sjogren\u2019s disease murine model","volume":"58","author":"Lin","year":"2026","journal-title":"Ann. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ard.2025.04.020","article-title":"Development of salivary gland organoids derived from patient biopsies: A functional model of Sjogren\u2019s disease","volume":"84","author":"Meudec","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1093\/rheumatology\/keaf173","article-title":"Evaluating the therapeutic potential of tofacitinib in Sjogren\u2019s disease: A comprehensive clinical and immunological assessment","volume":"64","author":"Liu","year":"2025","journal-title":"Rheumatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10238-024-01401-4","article-title":"Role of chemokines CXCL9, CXCL10, CXCL11, and CXCR3 in the serum and minor salivary gland tissues of patients with Sjogren\u2019s syndrome","volume":"24","author":"Kim","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liao, J., Yu, X., Huang, Z., He, Q., Yang, J., Zhang, Y., Chen, J., Song, W., Luo, J., and Tao, Q. (2024). Chemokines and lymphocyte homing in Sjogren\u2019s syndrome. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1345381"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"378","DOI":"10.55563\/clinexprheumatol\/gbjatf","article-title":"Interleukin 17E associates with haematologic involvement and autoantibody production in primary Sjogren\u2019s syndrome","volume":"39","author":"Zhao","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e002738","DOI":"10.1136\/rmdopen-2022-002738","article-title":"Possible role for IL-40 and IL-40-producing cells in the lymphocytic infiltrated salivary glands of patients with primary Sjogren\u2019s syndrome","volume":"9","author":"Guggino","year":"2023","journal-title":"RMD Open"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"uxae087","DOI":"10.1093\/cei\/uxae087","article-title":"Increased expression of CXCL10 and CCL3 salivary gland chemokines in primary Sjogren\u2019s syndrome detected and systematically quantified using RNAscope(R)in situ hybridization","volume":"219","author":"Borge","year":"2025","journal-title":"Clin. Exp. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chatzis, L., Goules, A.V., Stergiou, I.E., Voulgarelis, M., Tzioufas, A.G., and Kapsogeorgou, E.K. (2021). Serum, but Not Saliva, CXCL13 Levels Associate with Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjogren\u2019s Syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.705079"},{"key":"ref_87","first-page":"582","article-title":"Salivary cytokines in Sjogren disease patients and its association with caries experience, sialometry, and systemic comorbidities: A pioneering study","volume":"56","author":"Aizenbud","year":"2025","journal-title":"Quintessence Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e1277","DOI":"10.1002\/cti2.1277","article-title":"IL-17 drives salivary gland dysfunction via inhibiting TRPC1-mediated calcium movement in Sjogren\u2019s syndrome","volume":"10","author":"Xiao","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.4049\/jimmunol.2101070","article-title":"The IL-33\/ST2 Axis Promotes Primary Sjogren\u2019s Syndrome by Enhancing Salivary Epithelial Cell Activation and Type 1 Immune Response","volume":"208","author":"Dong","year":"2022","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"107524","DOI":"10.1016\/j.phrs.2024.107524","article-title":"Therapeutic potential of interleukin-17 neutralization in a novel humanized mouse model of Sjogren\u2019s disease","volume":"210","author":"Yu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sjogren syndrome: A multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren\u2019s syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren\u2019s syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.coi.2025.102712","article-title":"Mapping the B-cell axis in Sjogren\u2019s disease: Repertoire, microenvironment, and potential routes to precision treatment","volume":"98","author":"Chatzis","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sjogren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Li, L., Shen, S., Shao, S., Dang, E., Wang, G., Fang, H., and Qiao, H. (2025). The role of B cell-activating factor system in autoimmune diseases: Mechanisms, disease implications, and therapeutic advances. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1538555"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"131","DOI":"10.55563\/clinexprheumatol\/fp741f","article-title":"Serum CXCL13, BAFF, IL-21 and IL-22 levels are related to disease activity and lymphocyte profile in primary Sjogren\u2019s syndrome","volume":"39","author":"Palacio","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u2019s syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren\u2019s syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J. Clin. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e004112","DOI":"10.1136\/rmdopen-2024-004112","article-title":"Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjogren\u2019s disease","volume":"10","author":"Felten","year":"2024","journal-title":"RMD Open"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: Results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren\u2019s syndrome: A randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sjogren\u2019s syndrome: A randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102739","DOI":"10.1016\/j.coi.2026.102739","article-title":"T cells in Sjogren\u2019s disease: Update on their role in salivary gland pathogenesis and treatment","volume":"99","author":"Verstappen","year":"2026","journal-title":"Curr. Opin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Verstappen, G.M., Gao, L., Pringle, S., Haacke, E.A., van der Vegt, B., Liefers, S.C., Patel, V., Hu, Y., Mukherjee, S., and Carman, J. (2021). The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients with Primary Sjogren\u2019s Syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.681941"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Yamada, E., Dominick, K., Kulchar, R.J., Twohig, J., Khavandgar, Z., Beach, M., Pelayo, E., Baer, A., Perez, P., and Warner, B.M. (2025). Multiparameter flow cytometry enables immune profiling and IFN pathway analysis in human minor salivary glands. Front. Dent. Med., 6.","DOI":"10.3389\/fdmed.2025.1590516"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41467-024-54686-0","article-title":"Molecular and spatial analysis of tertiary lymphoid structures in Sjogren\u2019s syndrome","volume":"16","author":"Nayar","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.41558","article-title":"Interleukin-7\/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjogren\u2019s Syndrome","volume":"73","author":"Riviere","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Meng, Q., Ma, J., Cui, J., Gu, Y., and Shan, Y. (2024). Subpopulation dynamics of T and B lymphocytes in Sjogren\u2019s syndrome: Implications for disease activity and treatment. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1468469"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"15427","DOI":"10.1038\/s41598-022-19397-w","article-title":"Cytotoxic CD8(+) T cells may be drivers of tissue destruction in Sjogren\u2019s syndrome","volume":"12","author":"Kaneko","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_113","unstructured":"Pranzatelli, T.J.F., Perez, P., Ku, A., Matuck, B., Huynh, K., Sakai, S., Abed, M., Jang, S.I., Yamada, E., and Dominick, K. (2025). GZMK(+)CD8(+) T cells target a specific acinar cell type in Sjogren\u2019s disease. Ann. Rheum. Dis., in press."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10067-022-06491-7","article-title":"Alterations of CD8(+) T cells in the blood and salivary glands of patients with primary Sjogren\u2019s syndrome","volume":"42","author":"Li","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1016\/S2665-9913(25)00181-X","article-title":"Machine learning to classify the focus score and Sjogren\u2019s disease using digitalised salivary gland biopsies: A retrospective cohort study","volume":"7","author":"Duquesne","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"17256","DOI":"10.1038\/s41598-024-67901-1","article-title":"Role of mucosal-associated invariant T cells dynamics in pathogenesis of Sjogren syndrome","volume":"14","author":"Chauffier","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/eji.201646300","article-title":"Mucosal-associated invariant T cells are reduced and functionally immature in the peripheral blood of primary Sjogren\u2019s syndrome patients","volume":"46","author":"Wang","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Ciesielska-Figlon, K., and Lisowska, K.A. (2024). The Role of the CD28 Family Receptors in T-Cell Immunomodulation. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021274"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sjogren\u2019s syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sjogren\u2019s syndrome: Results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sjogren\u2019s syndrome: A single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"Mossel","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"151955","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary Sjogren\u2019s syndrome: The open-label extension phase of the ASAP-III trial","volume":"53","author":"Mossel","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_124","first-page":"317","article-title":"Abatacept treatment of patients with primary Sjogren\u2019s syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_125","first-page":"2362","article-title":"Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sjogren\u2019s disease patients","volume":"42","author":"Nakshbandi","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3892\/mmr.2022.12864","article-title":"Expression of ICOS in the salivary glands of patients with primary Sjogren\u2019s syndrome and its molecular mechanism","volume":"26","author":"Li","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Luo, J., Liao, X., Zhang, L., Xu, X., Ying, S., Yu, M., Zhu, L., Lin, S., and Wang, X. (2020). Transcriptome Sequencing Reveals Potential Roles of ICOS in Primary Sjogren\u2019s Syndrome. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.592490"},{"key":"ref_128","first-page":"222","article-title":"Blocking T cell co-stimulation in primary Sjogren\u2019s syndrome: Rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers","volume":"38","author":"Pontarini","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e2241451","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjogren Syndrome: A Randomized Clinical Trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/art.43144","article-title":"Identification of Pathogenic PD-1(+)CD8(+) T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sjogren Disease","volume":"77","author":"Ma","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"102549","DOI":"10.1016\/j.jaut.2020.102549","article-title":"Fingolimod reduces salivary infiltrates and increases salivary secretion in a murine Sjogren\u2019s model","volume":"115","author":"Cohen","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"106935","DOI":"10.1016\/j.imlet.2024.106935","article-title":"Fingolimod, an antagonist of sphingosine 1-phosphate, ameliorates Sjogren\u2019s syndrome by reducing the number of STAT3-induced germinal center B cells and increasing the number of Breg cells","volume":"270","author":"Lee","year":"2024","journal-title":"Immunol. Lett."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2011-11-391144","article-title":"Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome","volume":"120","author":"Xu","year":"2012","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s13287-021-02541-0","article-title":"Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sjogren\u2019s syndrome by modulating the balance of Treg and Th17 cells","volume":"12","author":"Li","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sjogren\u2019s syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Riviere","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.autrev.2011.10.005","article-title":"In Sjogren\u2019s syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation","volume":"11","author":"Varin","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Du, W., Han, M., Zhu, X., Xiao, F., Huang, E., Che, N., Tang, X., Zou, H., Jiang, Q., and Lu, L. (2021). The Multiple Roles of B Cells in the Pathogenesis of Sjogren\u2019s Syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.684999"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.20276","article-title":"Abnormalities in peripheral B cell memory of patients with primary Sjogren\u2019s syndrome","volume":"50","author":"Hansen","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/ar2210","article-title":"B cells in Sjogren\u2019s syndrome: Indications for disturbed selection and differentiation in ectopic lymphoid tissue","volume":"9","author":"Hansen","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/art.21129","article-title":"Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren\u2019s syndrome","volume":"52","author":"Hansen","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","article-title":"Pathogenetic mechanisms in the initiation and perpetuation of Sjogren\u2019s syndrome","volume":"6","author":"Voulgarelis","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_142","first-page":"1988","article-title":"CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren\u2019s syndrome","volume":"7","author":"Jin","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jaci.2016.01.024","article-title":"Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren\u2019s signature correlating with disease activity and glandular inflammation","volume":"137","author":"Mingueneau","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/08916934.2019.1684475","article-title":"Autoantigen-specific B cells and plasma cells are prominent in areas of fatty infiltration in salivary glands of patients with primary Sjogren\u2019s syndrome","volume":"52","author":"Skarstein","year":"2019","journal-title":"Autoimmunity"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood-2011-01-331462","article-title":"Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell population is important for the development of autoimmunity","volume":"118","author":"Rubtsov","year":"2011","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"E3216","DOI":"10.1073\/pnas.1312348110","article-title":"T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance","volume":"110","author":"Rubtsova","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1007\/s11357-024-01159-3","article-title":"Age-associated B cell infiltration in salivary glands represents a hallmark of Sjogren\u2019s-like disease in aging mice","volume":"46","author":"Bagavant","year":"2024","journal-title":"Geroscience"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2017.03.012","article-title":"FcRL4(+) B-cells in salivary glands of primary Sjogren\u2019s syndrome patients","volume":"81","author":"Haacke","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_149","first-page":"42","article-title":"Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjogren\u2019s syndrome patients","volume":"37","author":"Haacke","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"102439","DOI":"10.1016\/j.jaut.2020.102439","article-title":"Gene expression profiling of epithelium-associated FcRL4(+) B cells in primary Sjogren\u2019s syndrome reveals a pathogenic signature","volume":"109","author":"Verstappen","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1002\/art.21936","article-title":"Identification of transitional type II B cells in the salivary glands of patients with Sjogren\u2019s syndrome","volume":"54","author":"Daridon","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2016.04.008","article-title":"Central role for marginal zone B cells in an animal model of Sjogren\u2019s syndrome","volume":"168","author":"Shen","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bjh.15120","article-title":"Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjogren syndrome (pSS)","volume":"184","author":"Demaria","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e12718","DOI":"10.1111\/sji.12718","article-title":"Aberrant IL-35 levels in patients with primary Sjogren\u2019s syndrome","volume":"88","author":"Guo","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"35815","DOI":"10.1038\/s41598-025-19796-9","article-title":"Decreased IgD-CD27-double negative B cells in Sjogren\u2019s disease correlated with disease activity index","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41588-021-00803-4","article-title":"Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice","volume":"53","author":"Wang","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1002\/iid3.934","article-title":"Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases","volume":"11","author":"Zhou","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Neys, S.F.H., Hendriks, R.W., and Corneth, O.B.J. (2021). Targeting Bruton\u2019s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.668131"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/1744666X.2025.2522265","article-title":"Phosphoinositide-3-kinase delta as an immune check-pathway in cancer Immunology. Therapeutic prospects","volume":"21","author":"Corbi","year":"2025","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2017-212619","article-title":"Phosphatidylinositol 3-kinase delta pathway: A novel therapeutic target for Sjogren\u2019s syndrome","volume":"78","author":"Nayar","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/imm.13580","article-title":"mTORC1-GLUT1-mediated glucose metabolism drives hyperactivation of B cells in primary Sjogren\u2019s syndrome","volume":"168","author":"Luo","year":"2023","journal-title":"Immunology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"123884","DOI":"10.1016\/j.lfs.2025.123884","article-title":"M6A modification of RRM2 drives B cell hyperactivity in primary Sjogren\u2019s syndrome","volume":"379","author":"Yang","year":"2025","journal-title":"Life Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren\u2019s Syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: A randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: A randomized trial","volume":"160","author":"Mariette","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: Results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren\u2019s syndrome: An open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard-2023-224999","article-title":"Obinutuzumab in patients with Sjogren\u2019s disease immunised against rituximab","volume":"83","author":"Pezot","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren\u2019s syndrome: Results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"Dorner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/rheumatology\/kead092","article-title":"A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjogren\u2019s syndrome","volume":"62","author":"Bentley","year":"2023","journal-title":"Rheumatology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical Efficacy and Safety of Baminercept, a Lymphotoxin beta Receptor Fusion Protein, in Primary Sjogren\u2019s Syndrome: Results from a Phase II Randomized, Double-Blind, Placebo-Controlled Trial","volume":"70","author":"Baer","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s40001-024-01967-5","article-title":"Primary Sjogren\u2019s syndrome: New perspectives on salivary gland epithelial cells","volume":"29","author":"Hou","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e2300173","DOI":"10.1002\/adbi.202300173","article-title":"Modes and Mechanisms of Salivary Gland Epithelial Cell Death in Sjogren\u2019s Syndrome","volume":"7","author":"Zhou","year":"2023","journal-title":"Adv. Biol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1038\/s41598-023-28857-w","article-title":"LAMP3 transfer via extracellular particles induces apoptosis in Sjogren\u2019s disease","volume":"13","author":"Tanaka","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s10495-008-0261-2","article-title":"Rapid and significant induction of TRAIL-mediated type II cells in apoptosis of primary salivary epithelial cells in primary Sjogren\u2019s syndrome","volume":"13","author":"Nakamura","year":"2008","journal-title":"Apoptosis"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/art.42018","article-title":"Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjogren\u2019s Syndrome","volume":"74","author":"Colafrancesco","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41422-025-01107-6","article-title":"Pyroptosis: Molecular mechanisms and roles in disease","volume":"35","author":"Broz","year":"2025","journal-title":"Cell Res."},{"key":"ref_180","first-page":"2172","article-title":"Machine learning-based identification of pyroptosis-related genes as biomarkers and targets in primary Sjogren\u2019s syndrome","volume":"43","author":"Jiang","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1538054","DOI":"10.1155\/mi\/1538054","article-title":"Identification and Validation of Pyroptosis-Associated Gene Signature in Primary Sjogren\u2019s Syndrome","volume":"2025","author":"Dai","year":"2025","journal-title":"Mediat. Inflamm."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/joim.12115","article-title":"The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjogren\u2019s syndrome","volume":"274","author":"Baldini","year":"2013","journal-title":"J. Intern. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.4110\/in.2020.20.e39","article-title":"Type I Interferon Increases Inflammasomes Associated Pyroptosis in the Salivary Glands of Patients with Primary Sjogren\u2019s Syndrome","volume":"20","author":"Hong","year":"2020","journal-title":"Immune Netw."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2023.05.027","article-title":"Interferon-gamma induces salivary gland epithelial cell ferroptosis in Sjogren\u2019s syndrome via JAK\/STAT1-mediated inhibition of system Xc()","volume":"205","author":"Cao","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"167121","DOI":"10.1016\/j.bbadis.2024.167121","article-title":"CD4 T cell-secreted IFN-gamma in Sjogren\u2019s syndrome induces salivary gland epithelial cell ferroptosis","volume":"1870","author":"Zhou","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00109-026-02649-x","article-title":"Galectin-9 potentiates salivary gland damage by inducing ferroptosis in Sjogren\u2019s disease","volume":"104","author":"Liu","year":"2026","journal-title":"J. Mol. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2024.04.003","article-title":"Downregulated GPX4 in salivary gland epithelial cells contributes to salivary secretion dysfunction in Sjogren\u2019s syndrome via lipid ROS\/pSTAT4\/AQP5 axis","volume":"218","author":"Zhou","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"113409","DOI":"10.1016\/j.intimp.2024.113409","article-title":"Apigenin alleviates Sjogren\u2019s syndrome-induced salivary gland epithelial cell ferroptosis via ERalpha signaling-mediated regulation of the ATF3\/SLC7A1l axis","volume":"143","author":"Liu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s11658-024-00667-6","article-title":"Salivary gland protective and antiinflammatory effects of genistein in Sjogren\u2019s syndrome by inhibiting Xist\/ACSL4-mediated ferroptosis following binding to estrogen receptor-alpha","volume":"29","author":"Mao","year":"2024","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00011-025-02047-y","article-title":"Melatonin inhibits salivary gland epithelial cell ferroptosis via the NRF2\/HO-1\/GPX4 signaling pathway in primary Sjogren\u2019s syndrome","volume":"74","author":"Weng","year":"2025","journal-title":"Inflamm. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"102867","DOI":"10.1016\/j.autrev.2021.102867","article-title":"Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjogren\u2019s syndrome","volume":"20","author":"Barrera","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_193","first-page":"1","article-title":"Mitochondrial Dysfunction and Immune Dysregulation in Primary Sjogren\u2019s Syndrome: Implications for Therapeutic Strategies","volume":"8","author":"Poznyak","year":"2024","journal-title":"J. Angiother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"103014","DOI":"10.1016\/j.jaut.2023.103014","article-title":"Salivary gland epithelial cell in Sjogren\u2019s syndrome: Metabolic shift and altered mitochondrial morphology toward an innate immune cell function","volume":"136","author":"Katsiougiannis","year":"2023","journal-title":"J. Autoimmun."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Li, N., Li, Y., Hu, J., Wu, Y., Yang, J., Fan, H., Li, L., Luo, D., Ye, Y., and Gao, Y. (2022). A Link Between Mitochondrial Dysfunction and the Immune Microenvironment of Salivary Glands in Primary Sjogren\u2019s Syndrome. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.845209"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Luo, D., Li, L., Wu, Y., Yang, Y., Ye, Y., Hu, J., Gao, Y., Zeng, N., Fei, X., and Li, N. (2023). Mitochondria-related genes and metabolic profiles of innate and adaptive immune cells in primary Sjogren\u2019s syndrome. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1156774"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"108511","DOI":"10.1016\/j.compbiomed.2024.108511","article-title":"Identification of key mitochondria-related genes and their relevance to the immune system linking Parkinson\u2019s disease and primary Sjogren\u2019s syndrome through integrated bioinformatics analyses","volume":"175","author":"Zong","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7150\/ijms.83801","article-title":"Lactate-induced mtDNA Accumulation Activates cGAS-STING Signaling and the Inflammatory Response in Sjogren\u2019s Syndrome","volume":"20","author":"Xu","year":"2023","journal-title":"Int. J. Med. Sci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.clinsp.2024.100459","article-title":"Targeted saliva metabolomics in Sjogren\u2019s syndrome","volume":"79","author":"Izidoro","year":"2024","journal-title":"Clinics"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Chivasso, C., Hagstromer, C.J., Rose, K.L., Lhotellerie, F., Leblanc, L., Wang, Z., Moscato, S., Chevalier, C., Zindy, E., and Martin, M. (2021). Ezrin Is a Novel Protein Partner of Aquaporin-5 in Human Salivary Glands and Shows Altered Expression and Cellular Localization in Sjogren\u2019s Syndrome. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179213"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keq033","article-title":"Aberrant localization of ezrin correlates with salivary acini disorganization in Sjogren\u2019s Syndrome","volume":"49","author":"Perez","year":"2010","journal-title":"Rheumatology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/art.27362","article-title":"Disruption of tight junction structure in salivary glands from Sjogren\u2019s syndrome patients is linked to proinflammatory cytokine exposure","volume":"62","author":"Ewert","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/0022034516634647","article-title":"Interleukin-17 Impairs Salivary Tight Junction Integrity in Sjogren\u2019s Syndrome","volume":"95","author":"Zhang","year":"2016","journal-title":"J. Dent. Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41368-025-00349-9","article-title":"Loss of tricellular tight junction tricellulin leads to hyposalivation in Sjogren\u2019s syndrome","volume":"17","author":"Mao","year":"2025","journal-title":"Int. J. Oral Sci."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Horeth, E., Oyelakin, A., Song, E.C., Che, M., Bard, J., Min, S., Kiripolsky, J., Kramer, J.M., Sinha, S., and Romano, R.A. (2021). Transcriptomic and Single-Cell Analysis Reveals Regulatory Networks and Cellular Heterogeneity in Mouse Primary Sjogren\u2019s Syndrome Salivary Glands. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.729040"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"117132","DOI":"10.1016\/j.celrep.2026.117132","article-title":"IL-4 triggers salivary duct dilatation via SHH signaling and exacerbates Sjogren\u2019s disease","volume":"45","author":"Zhang","year":"2026","journal-title":"Cell Rep."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.bbamcr.2018.07.002","article-title":"Calcium signaling defects underlying salivary gland dysfunction","volume":"1865","author":"Ambudkar","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Lee, B.H., Gauna, A.E., Perez, G., Park, Y.J., Pauley, K.M., Kawai, T., and Cha, S. (2013). Autoantibodies against muscarinic type 3 receptor in Sjogren\u2019s syndrome inhibit aquaporin 5 trafficking. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053113"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"114038","DOI":"10.1016\/j.jim.2026.114038","article-title":"Muscarinic 3 receptor antibodies in Sjogren\u2019s disease: Evaluating assay variability and detection methods","volume":"547","author":"Tsaliki","year":"2026","journal-title":"J. Immunol. Methods"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.2741\/4689","article-title":"Autoantibodies against muscarinic acetylcholine receptor M(3) in Sjogren\u2019s syndrome and corresponding mouse models","volume":"23","author":"Yu","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.012","article-title":"The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjogren\u2019s syndrome: A critical review","volume":"51","author":"Sumida","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"13953","DOI":"10.1038\/srep13953","article-title":"IP3R deficit underlies loss of salivary fluid secretion in Sjogren\u2019s Syndrome","volume":"5","author":"Teos","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"zqae047","DOI":"10.1093\/function\/zqae047","article-title":"Loss of STIM1 and STIM2 in Salivary Glands Disrupts ANO1 Function but Does Not Induce Sjogren\u2019s Disease","volume":"6","author":"Son","year":"2025","journal-title":"Function"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"14544","DOI":"10.1073\/pnas.1207354109","article-title":"STIM1 and STIM2 protein deficiency in T lymphocytes underlies development of the exocrine gland autoimmune disease, Sjogren\u2019s syndrome","volume":"109","author":"Cheng","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Collins, H.E., Zhang, D., and Chatham, J.C. (2022). STIM and Orai Mediated Regulation of Calcium Signaling in Age-Related Diseases. Front. Aging, 3.","DOI":"10.3389\/fragi.2022.876785"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"eado4856","DOI":"10.1126\/scitranslmed.ado4856","article-title":"IFN-gamma-producing T(H)1 cells and dysfunctional regulatory T cells contribute to the pathogenesis of Sjogren\u2019s disease","volume":"16","author":"Wang","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/ard.2007.078246","article-title":"Reduced sulfation of muc5b is linked to xerostomia in patients with Sjogren syndrome","volume":"67","author":"Alliende","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1074\/mcp.M115.052993","article-title":"Reduced Mucin-7 (Muc7) Sialylation and Altered Saliva Rheology in Sjogren\u2019s Syndrome Associated Oral Dryness","volume":"15","author":"Chaudhury","year":"2016","journal-title":"Mol. Cell Proteom."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/rheumatology\/kev026","article-title":"Salivary mucins induce a Toll-like receptor 4-mediated pro-inflammatory response in human submandibular salivary cells: Are mucins involved in Sjogren\u2019s syndrome?","volume":"54","author":"Barrera","year":"2015","journal-title":"Rheumatology"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Zhang, J.S., Chu, C.H., and Yu, O.Y. (2022). Oral Microbiome and Dental Caries Development. Dent. J., 10.","DOI":"10.3390\/dj10100184"},{"key":"ref_221","first-page":"1007","article-title":"Microflora in oral ecosystems in primary Sjogren\u2019s syndrome","volume":"28","author":"Almstahl","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s10067-024-06958-9","article-title":"Characteristics of the oral microbiota in patients with primary Sjogren\u2019s syndrome","volume":"43","author":"Xie","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bdj.2012.890","article-title":"Sjogren\u2019s syndrome\u2014An update for dental practitioners","volume":"213","author":"Carr","year":"2012","journal-title":"Br. Dent. J."},{"key":"ref_224","first-page":"e545","article-title":"Tooth loss in Sjogren\u2019s syndrome patients compared to age and gender matched controls","volume":"23","author":"Maarse","year":"2018","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Chuang, C.J., Hsu, C.W., Lu, M.C., and Koo, M. (2020). Increased risk of developing dental diseases in patients with primary Sjogren\u2019s syndrome-A secondary cohort analysis of population-based claims data. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0239442"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/154405910808700411","article-title":"Oral manifestations of Sjogren\u2019s syndrome","volume":"87","author":"Mathews","year":"2008","journal-title":"J. Dent. Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2019.04.011","article-title":"Risk factors for caries development in primary Sjogren syndrome","volume":"128","author":"Berman","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/000163501750266684","article-title":"Dental caries and dental health behavior of patients with primary Sjogren syndrome","volume":"59","author":"Christensen","year":"2001","journal-title":"Acta Odontol. Scand."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Pedersen, A.M., Bardow, A., and Nauntofte, B. (2005). Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren\u2019s syndrome. BMC Clin. Pathol., 5.","DOI":"10.1186\/1472-6890-5-4"},{"key":"ref_230","first-page":"151","article-title":"Salivary interleukin-1\u03b2 and Streptococcus mutans level in oral cavity","volume":"37","author":"Zaleska","year":"2012","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7150\/ijms.29027","article-title":"MUC7 Level as a New Saliva Risk Factor for Dental Caries in Adult Patients","volume":"16","author":"Ronij","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(05)67728-8","article-title":"Periodontal diseases","volume":"366","author":"Pihlstrom","year":"2005","journal-title":"Lancet"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.12771\/emj.2025.00101","article-title":"Relationship between periodontitis and systemic health conditions: A narrative review","volume":"48","author":"Kim","year":"2025","journal-title":"Ewha Med. J."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.oooo.2017.11.018","article-title":"Relationship between sjogren syndrome and periodontal status: A systematic review","volume":"125","author":"Rocha","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Gheorghe, D.N., Popescu, D.M., Dinescu, S.C., Silaghi, M., Surlin, P., and Ciurea, P.L. (2023). Association between Sjogren\u2019s Syndrome and Periodontitis: Epidemiological, Fundamental and Clinical Data: A Systematic Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13081401"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jds.2020.11.015","article-title":"Periodontal conditions in patients with Sjogren\u2019s syndrome: A meta-analysis","volume":"16","author":"Wu","year":"2021","journal-title":"J. Dent. Sci."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Yang, B., Pang, X., Guan, J., Liu, X., Li, X., Wang, Y., Chen, Z., and Cheng, B. (2022). The association of periodontal diseases and Sjogren\u2019s syndrome: A systematic review and meta-analysis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.904638"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"106167","DOI":"10.1016\/j.archoralbio.2024.106167","article-title":"Association between oral microbiome dysbiosis and Sjogren Syndrome. A systematic review of clinical studies","volume":"172","author":"Nagi","year":"2025","journal-title":"Arch. Oral Biol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-051X.1998.tb02419.x","article-title":"Microbial complexes in subgingival plaque","volume":"25","author":"Socransky","year":"1998","journal-title":"J. Clin. Periodontol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0003319709344576","article-title":"Periodontal disease and sjogren syndrome: A possible correlation?","volume":"61","author":"Scardina","year":"2010","journal-title":"Angiology"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/art.21205","article-title":"Is periodontal disease mediated by salivary BAFF in Sjogren\u2019s syndrome?","volume":"52","author":"Pers","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"e70713","DOI":"10.1111\/jcmm.70713","article-title":"Featured Immune Characteristics of Periodontitis and Primary Sjogren\u2019s Syndrome Revealed by Single-Cell Transcriptome Analyses","volume":"29","author":"Li","year":"2025","journal-title":"J. Cell Mol. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/14787210.2014.916210","article-title":"Pathogenicity mechanisms and host response during oral Candida albicans infections","volume":"12","author":"Hebecker","year":"2014","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/odi.12626","article-title":"Elucidating the role of hyposalivation and autoimmunity in oral candidiasis","volume":"23","author":"Billings","year":"2017","journal-title":"Oral Dis."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Xing, Y., Shi, H., Wang, C., and Yang, Y. (2024). Clinical features and risk factors for Sjogren\u2019s syndrome patients suffering from oral candidiasis in Shanxi, China. BMC Oral Health, 24.","DOI":"10.1186\/s12903-024-04595-x"},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Tamai, R., and Kiyoura, Y. (2025). Candida Infections: The Role of Saliva in Oral Health-A Narrative Review. Microorganisms, 13.","DOI":"10.3390\/microorganisms13040717"},{"key":"ref_247","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"102578","DOI":"10.1016\/j.coi.2025.102578","article-title":"Can we cure Sjogren\u2019s disease? Unmet needs and raising questions in the era of Precision medicine","volume":"95","author":"Chatzis","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Li, X.X., Maitiyaer, M., Tan, Q., Huang, W.H., Liu, Y., Liu, Z.P., Wen, Y.Q., Zheng, Y., Chen, X., and Chen, R.L. (2024). Emerging biologic frontiers for Sjogren\u2019s syndrome: Unveiling novel approaches with emphasis on extra glandular pathology. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1377055"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sjogren\u2019s disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert. Rev. Clin. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/4144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:29:57Z","timestamp":1778520597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/4144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":250,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27094144"],"URL":"https:\/\/doi.org\/10.3390\/ijms27094144","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}